Introduction
Chloramphenicol (CAM) [ Fig. 1(A) ] is a potent broadspectrum antibacterial agent. Since its isolation from Streptomyces venezuelae in 1948, 1 CAM was one of the primary agents used to treat many infections in the decades that followed. To date, despite its relatively high toxicity, 2 CAM is used in many countries because of its affordability and its broad spectrum of activity. In the Western world, CAM is used in treatment of ophthalmic infections and as a last resort in cases of life-threatening brain infections, such as those caused by Neisseria meningitidis, which do not respond to other agents. CAM's ability to cross the blood-brain barrier makes it a potent therapeutic against brain infections. Because of the emergence of pathogens resistant to multiple drugs, CAM is now being reconsidered as a wider-spectrum therapeutic.
with the ribosome through direct hydrogen bonding, potassium ion-mediated electrostatic interactions, as well as through van der Waals interactions with the RNA phosphosugar backbone. 4, 5 The 1-hydroxyl of CAM forms hydrogen bonds with RNA bases. Therefore, any modification of the 1-hydroxyl or the 3-hydroxyl of CAM is predicted to be disruptive of CAM-ribosome binding. 5 Bacterial resistance to CAM is caused by the chromosomally or plasmid-encoded enzyme chloramphenicol acetyltransferase (CAT) that catalyzes the transfer of an acetyl group from acetylcoenzyme A (AcCoA) to the 3-hydroxyl group of CAM [ Fig. 1(B) ]. 6 A subsequent slow, non-enzymatic transfer of this acetyl group to the neighboring 1-hydroxyl group allows for a second CAT-catalyzed acetyl transfer from AcCoA onto the 3-hydroxyl group of the same CAM molecule, resulting in a di-acetylated CAM. 7, 8 However, a single acetylation of CAM is sufficient to abolish its affinity for the ribosome 9 as explained by the above-mentioned structural observations. 4, 5 CAT proteins are historically divided into three types: CAT I , CAT II , and CAT III , with all three types capable of catalyzing the acetyl transfer to CAM to generate 3-O-acetyl-CAM. Genomic analysis of different CAT sequences indicates that the boundaries between these CAT types are not sharp. Members of the CAT I family are present in many important pathogens such as E. coli, Shigella flexneri, Serratia marcescens, and Salmonella enterica. CAT I family enzymes display high sequence conservation among themselves (e.g. S. flexneri and S. marcescens CAT I proteins are 98% and 99% identical to E. coli CAT I , respectively); however, they display only a modest sequence identity to CAT II ($46%) and CAT III (32-47%) (Fig. 2) . The CAT II family is not easily distinguishable from CAT III and has been defined historically only through its extreme susceptibility to thiol-modifying agents compared with that of CAT I and CAT III . 11 There are no obvious additional Cys residues or other sequence features in CAT II distinguishing it from the CAT III variants. A slight variation in the pK a of the Cys31 (in CAT III nomenclature), the only Cys in vicinity of the substrate or the cosubstrate binding sites, was suggested to be responsible for the difference in reactivity with thiol-modifying agents, 12 although there is no evidence confirming this idea. The sequence differences between CAT I and CAT III include several substitutions in the binding site (Fig. 2) , potentially resulting in positional differences of CAM bound to these two proteins. A major consequence of this divergence is reflected in different substrate selectivities of CAT I and CAT III . In addition to binding and modifying CAM, 6 CAT I , unlike CAT III , binds a much bulkier antibiotic, Herein we report crystal structures of CAT I alone (apo) and in complex with CAM, which explain how CAT I binds CAM despite differences in its binding site residues from those in CAT III . Analysis of these structures along with that of the structure of CAT I in complex with FA (deposited in the Protein Data Bank (PDB) by Roidis and Kokkinidis; accession code: 1Q23 35 ) provides an explanation of the differences in substrate preference among CAT types.
Results
Overall structure of CAT I E. coli CAT I protein was initially co-crystallized with CAM in the P1 space group (Table I) . Molecular replacement using either a monomer or trimer of apo-CAT I (from the structure of a serendipitous complex of the nitric oxide synthase oxygenase domain with CAT I ; PDB code: 1NOC 37 ) as a search model did not yield a solution. This complication likely arose due to the presence of several copies of the protein molecules within a very large unit cell. Further crystallization trials yielded crystals of CAT I alone in the P2 1 space group with a smaller asymmetric unit. These crystals grew under conditions similar to those of the CAT I -CAM crystals. Molecular replacement with a CAT I trimer from the 1NOC entry as a search model, yielded an apo-CAT I structure with three CAT I trimers in the asymmetric unit (Table I ). This three-trimer structure was then successfully used as a molecular replacement search model to determine the structure of the CAT I -CAM complex in the P1 crystal form. The asymmetric unit of the P1 crystal form contained six CAT I -CAM trimers. The crystal structure of the apo-CAT I and that of the CAT I -CAM complex were refined to 3.2 Å and 2.9 Å resolution, respectively (Table I ). The structure of CAT I protein in the apo form reported here is very similar to the structure of apo-CAT I (PDB code: 1NOC) used for the molecular replacement (Ca RMSD ¼ 0.7 Å ) and to another previously deposited structure of apo-CAT I (PDB code: 1PD5; Ca RMSD ¼ 0.7 Å ). Furthermore, the structures of apo-CAT I are highly similar to the structure of CAT I in complex with CAM (Ca RMSD $ 0.4 Å ), suggesting that no major protein conformational changes occur upon CAM binding. Analogously, no major conformational differences were observed for CAT III in the apo and the CAM-bound forms. 28 The overall fold and the oligomeric organization of CAT I [ Fig. 3 (A)] resemble those of the previously characterized CAT III 28 variant. Three identical monomers of CAT I form a trimer with a 3-fold rotational symmetry. The overall trimeric scaffold is formed by three 7-stranded b-sheets, each of which is formed by six strands (b6, b5, b7, b9, b10, and b2) from one monomer and one strand (b8) from another monomer [ Fig. 3(B) ]. In each monomer, this b-sheet is flanked on the outside by five a-helices and a small three-stranded b-sheet. In the trimeric core, the aliphatic parts of buried Asp157 side-chains (in strand b8) of the three monomers come together to form intimate hydrophobic contacts with each other, while their carboxyl groups are engaged in intricate, asymmetric network of hydrogen bonding interactions with the side-chains of Ser155 and Asn159. The hydrophobic interactions between the Asp157 residues are likely critical for complex stability as this residue is either an Asp or an Asn in most CAT I /CAT III proteins. Ser155 could however be substituted by a Gly (Fig. 2) . The side-chains of Asp157 residues are distorted so that the carboxyl groups form hydrogen bonds with their own backbone amide NH moieties justifying a weaker conservation of the Ser155. As the side-chains in these b-strands are generally buried away from the solvent, their identities are well conserved among CAT homologs.
Chloramphenicol interactions in the active site
Upon trimerization, the active site is formed at the interface of two b-sheets predominantly with residues from strands b6, b5, b7, b9, and b8 of one monomer (termed as the binding monomer) and strands b2 and b10 of the other (the catalytic monomer). Each trimer contains three identical substrate binding sites [ Fig. 3(A) ]. The nature of this conserved trimeric assembly strongly suggests that CAT I monomers either require trimeric assembly for proper folding or, if folded, CAT I would be catalytically active only in the context of a trimer. Indeed, monomeric mutants of the CAT III , whose overall fold is highly similar to that of CAT I , were shown to be catalytically inactive. 38 Below, we discuss features of the active site of CAT I and highlight its differences from that of CAT III that specify the distinct substrate recognition properties of these two proteins.
In the structure of CAT I -CAM complex, all three active site pockets of the CAT I trimer are occupied with CAM molecules [ Fig. 3(A) ], whose positions are clearly defined in the electron density map [ Fig. 3(C,D) ]. One of the two monomers forming a binding site (called here the binding monomer) provides the majority of the residues (Cys91, Phe102, Ser104, Phe134, Phe144, Ser146, Leu158, and Val170) involved in binding of the CAM while the other one (called here the catalytic monomer) provides His193, which has been demonstrated to be one of the primary conserved catalytic residues 7, 39, 40 [ Fig. 3(B) ]. A few other residues from the catalytic monomer (Phe25 and Cys31) also provide an important CAM-binding surface in the binding pocket. The disposition of the conserved catalytic residues [e.g. His193, Ser146, and Asp197; highlighted in red in Fig. 3(B) ] in the CAT I -CAM structure is highly similar to that observed previously in CAT III -CAM complex. 41 The position of His193, the likely general base, relative to the bound CAM is identical to its counterpart in CAT III (His195). The Ne2 atom of His193 is located 2.7 Å away from the 3-hydroxyl of CAM [ Fig. 3(E with FA bound). This conformation likely ensures that the imidazole ring is aligned appropriately for abstracting the 3-hydroxyl proton of CAM, promoting a nucleophilic attack by the oxygen on the acetyl group carbonyl of AcCoA, 29, 30, 34 similarly to the proposed mechanism of the CAT III variant. 40 The imidazole ring of His193 is positioned at a proper distance (approximately 3.6 Å ) for a faceto-face p-p stacking contact with Phe25. This overall structural arrangement of the catalytic monomer for proper positioning of His193 at the subunit interface is stabilized by several interactions that include a chain of hydrogen bonds between His193, Asp197, Arg18, and the backbone carbonyl oxygen of Ala194 [ Fig. 3(E) ]. The conserved Ser146 (another catalytically important residue) of CAT I is positioned similarly in the active site of all three CAT I structures, and likely stabilizes the transition state oxyanion by donating a hydrogen bond (possibly water-mediated in CAT I ), as proposed for Ser148 of CAT III . 42 The sequence alignment of CAT I and CAT III from E. coli demonstrates that of the 20 amino acid residues lining the CAM binding site, 9 are different between the two types (Fig. 2, blue circles) . These differences [Ala24 (CAT III , Phe24), Phe25 (CAT III , Tyr25), Val28 (CAT III , Arg28) Ala29 (CAT III , Leu29), Cys91 (CAT III , Gln92), Tyr133 (CAT III , Leu134), Phe144 (CAT III , Asn146), Phe166 (CAT III , Tyr168), and Val170 (CAT III , Ile172)] are significant as they include changes in the size and hydrophobicity of the residues. Remarkably, despite these differences, CAM binding affinities for CAT I and CAT III appear to be very similar. 43 Furthermore, the superposition of 
Fusidic acid interactions in the active site
In the CAT I -FA complex [ Fig. 4(A) ], FA occupies the same binding site as CAM, which explains its observed behavior as a competitive inhibitor of CAM acetylation. 13 The differences between the active site residues of CAT I (as described above) and those of CAT III , while having little effect on CAM binding, 41 ,44 create a unique surface suitable for binding to FA in CAT I . In particular, the placement of Ala24
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and Ala29 of CAT I shapes the substrate binding cavity such that the ring D and the 2-methylhex-2-ene ''tail'' of FA can be accommodated. The hydrophobic steroid ring system of FA makes numerous hydrophobic contacts with active site residues, including Thr93, Phe102, Phe134, Phe144, Ser146, Phe156, Leu158, Val160, Phe166, and Val170 of the binding subunit, as well as Ala24, Phe25, Val28, and Ala29 of the catalytic subunit [ Fig. 4(A,C) ]. The hydroxyl moiety of ring A of FA closely aligns with the 3-hydroxyl of CAM and forms a very strong hydrogen bond with the Ne2 atom of His193 at a distance of 2.9 Å [Fig. 4(C) ]. The hydroxyl group of Tyr133 points inward towards the binding pocket forming a hydrogen bond with the hydroxyl moiety of ring C, the atoms being separated by a distance of about 2.6 Å [ Fig. 4(C) ], similarly to the interaction between the 3-hydroxyl and Tyr133 in the CAT I -CAM structure [ Fig. 3(E) ]. Residues from both the binding monomer (Phe134) and the catalytic monomer (Ala24 and Val28) form a hydrophobic zone near the entrance of the binding pocket in CAT I that cradle the ''tail'' section of FA and dictate its conformation [ Fig. 4(A,C) ]. Valuable insight can be gained by comparing this structure with the previously reported structures of CAT III in complex with CAM 29 and a quadruple mutant of CAT III in complex with FA. 43 In the quadruple mutant of CAT III , four catalytic pocket residues were mutated (Gln92Cys/Asn146Phe/ Tyr168Phe/Ile172Val) to mimic those of CAT I . This comparison [ Fig. 4(B) ] indicates a disruption of the FA tail-interacting hydrophobic zone in the quadruple mutant of CAT III , in particular due to the Ala24-Phe and Val28Arg substitutions. The carboxylic acid and acetoxy moieties of ring D are highly solvent exposed when bound to both CAT I and the CAT III mutant. The acetoxy group of FA makes a hydrophobic contact with Phe166 in CAT I (Phe168 in CAT III ) [ Fig. 4(C,D) ]. Despite the same general protein backbone scaffold of CAT I and the mutant CAT III structures, there are several differences in the FA-protein contacts for the two enzymes. Most strikingly, several bulkier residues of CAT III : Phe24 (Ala24 in CAT I ), Tyr25 (Phe25 in CAT I ), Arg28 (Val28 in CAT I ), and Leu29 (Ala29 in CAT I ) prevent the FA molecule from binding in a position similar to that in CAT I . A required shift of the FA molecule must not be accommodated due to structural rigidity of wild-type CAT III resulting in the lack of binding to FA. The mutations of the CAT III quadruple mutant apparently relax this rigidity and surprisingly accommodate the FA molecule in a very different position from that seen in the CAT I -FA structure. The hydrophobic ''tail'' of FA now adopts a very different conformation and gets buried in the disordered loop region (residues 138-141) of the CAT III mutant. This disorder is very likely due to both the Asn146Phe and the Gln92Cys substitutions in the CAT III mutant, which cause displacement of the His144 and Thr140 side-chains, respectively, thereby distorting the local backbone. This displacement allows the FA-tail to occupy its altered position in the CAT III mutant. 43 Notably, Tyr25 in the CAT III quadruple mutant structure (positionally analogous to Phe25 of CAT I ) forms hydrogen bond with FA, at a distance of 2.8 Å to the hydroxyl on the A-ring [ Fig.  4(D) ], and stabilizes the altered FA orientation. Phe168 and Val172 residues in the CAT III quadruple mutant make direct hydrophobic contacts with the FA molecule, which explains the contribution of these substitutions to the change in binding affinity to FA. 43 We observe no major differences in the backbone conformations near the active site of CAT I in the structures of apo-CAT I (PDB code: 3U9B), CAT I bound to CAM (PDB code: 3U9F), and CAT I bound to FA (PDB code: 1Q23 35 ). This strongly suggests that CAT I has evolved to bind multiple ligands, even as large as an FA molecule, without any major protein conformational changes in its backbone.
Discussion
Chloramphenicol acetyltransferase (CAT) is found in many pathogenic bacteria and is often the cause of resistance against chloramphenicol (CAM), once a widely used antibiotic. Of many known CATs, the type-I appears to be the most prevalent. Recent studies have found CAT I in many pathogenic bacteria. CAT I has a preference for binding to a variety of substrates; not only does it inactivate CAM but it also binds and sequesters other antibiotics such as FA. A clear understanding of the mechanism of substrate binding by CAT I is important to address the intriguing question of how CAT proteins from different classes with similar overall structures display different substrate selectivity profiles. In comparison to CAT III that has been studied almost exclusively, there are only few mechanistic studies that have been performed on CAT I . The general fold and the trimeric organization of CAT proteins have been observed in enzymes of primary metabolic pathways in bacteria and eukaryotes, such as pyruvate dehydrogenases 45, 46 and a-keto acid dehydrogenases. 47, 48 Therefore, CAT appears to be a product of an ancient gene duplication event, which underwent subsequent specialization through evolution to serve a protective role against toxic compounds such as CAM. The general catalytic mechanism proposed for CAT proteins is based on studies of many such proteins. The residue primarily responsible for catalysis of CAT I appears to be His193 (His195 in CAT III ). 28 This role was proposed based on a previous study in which a mutant CAT III (His195Tyr) was shown to be devoid of catalytic activity. 49 Another conserved residue, Ser146, likely stabilizes the oxyanion formed upon an attack on the AcCoA carbonyl carbon by the 3-hydroxyl of CAM. Mutagenesis studies with CAT III confirmed that Ser148 (Ser146 in CAT I ) is crucial for efficient catalysis. 42 The CAT I protein structure is similar in the apo form and in the CAM-and the FA-bound states, indicating that no major changes in the backbone conformations or in positions of the side-chains occur upon ligand binding. It is quite remarkable that such nearly rigid scaffold is evolutionarily conserved and yet CAT I can bind chemically diverse substrates. Analysis of the aligned sequences shows that several residues of CAT I are different than corresponding residues in CAT III . Our investigation of the CAT I structures indicates that many of these differences are in residues lining the substrate binding pocket (Fig. 2, blue circles) . The most striking differences are concentrated around a small patch of residues (Ala24-Cys31, contributed by the catalytic monomer) that enable the FA molecule to be accommodated only in the pocket of CAT I . The bulkier residues of CAT III in this patch would push the FA towards the opposite side of the pocket and consequently disrupt the structure. Interestingly, the flexibility (apparently resulting in the reduced rigidity and increased disorder of the backbone) of the quadruple mutant of CAT III helps it accommodate the pushed out FA in a different conformation. The ''tail'' of FA now finds a different hydrophobic pocket to rest in and in turn provides stability to the FA in this altered binding pocket. The mutant CAT III shows a 200-fold higher affinity to FA than the wild-type CAT III . However, the quadruple mutant of CAT III binds FA with a much (4-fold) weaker affinity 43 than CAT I . In addition, the K m for CAM acetylation by the CAT III quadruple mutant was somewhat compromised (with respect to either CAT I or CAT III ) and the value of k cat was between those for CAT III and CAT I . With the direct structural evidence, it is now clear how the tail of FA nests in a hydrophobic pocket and renders CAT I more energetically favorable to bind to FA. In CAT III , a similarly positioned FA ''tail'' would be sterically blocked by Phe24 and Arg28, and it is not surprising that CAT III does not show affinity towards FA. Our understanding of CAM's mechanism of action as well as the mechanisms of resistance to it were largely based on biochemical and structural information available on CAM binding to CAT III and to the bacterial ribosome. 4 The present structural study augments this knowledge by filling in the gap in our understanding of the recognition of both CAM and FA by CAT I . CAM has been largely removed from the clinic in the Western world due to its safety concerns, even though cases of extreme toxicity are exceedingly rare. CAM has remained a popular drug in underdeveloped areas due to its low cost and effectiveness against a variety of pathogens. However, as with other antibiotics, development of resistance against CAM is a major obstacle to its power to save lives. The detailed picture of the CAT I structure is expected to aid in design of inhibitors of CAT enzymes that could re-sensitize CAM-resistant strains. In addition, structure-guided design of CAM analogs could lead to new antibiotics of this class that would be less toxic and more refractory to inactivation by CAT.
Materials and Methods

Expression and purification of CAT I
CAT I was expressed in BL21 (DE3)/RIL cells (Stratagene), which harbor a plasmid containing a constitutively expressed CAM resistance gene camR encoding untagged CAT I protein. The cells were grown in LB medium (200 rpm, 37 C) containing CAM (25 lg/mL) until the culture reached an attenuance of 0.4 at 600 nm. The cells were harvested after an additional 3 h growth. Pelleted cells (centrifugation at 5,000 g, 10 min, 4 C) were resuspended in the lysis buffer [MES pH 6.5 (40 mM), NaCl (200 mM), glycerol (5%), b-mercaptoethanol (2 mM), and EDTA (0.1 mM)] and lysed by sonication. The lysate was clarified by centrifugation at 35,000 Â g for 45 min at 4 C. We took advantage of the thermostability of CAT proteins 50 in purifying CAT I without an affinity tag. The clarified lysate was heated (75 C, 20 min) and subsequently centrifuged (35,000 Â g, 45 min, 4 C) to remove unfolded precipitated proteins. The CAT I in the soluble fraction was further purified by size-exclusion chromatography on an S-200 column (GE Healthcare) equilibrated with buffer [Tris pH 8.0 (40 mM) and NaCl (100 mM)]. The fractions containing pure CAT I , as determined by SDS-PAGE, were concentrated to 5 mg/mL using an Amicon Ultra centrifugal filter device (Millipore) and used for crystallization.
Crystallization of CAT I alone and in complex with CAM Crystals of CAT I alone and a complex of CAT I with CAM (CAT I -CAM) were grown by vapor diffusion in hanging drops containing 1 lL of protein and 1 lL of the reservoir solution [HEPES (100 mM) pH 7.5 (pH of 1 M stock of HEPES acid was adjusted by adding NaOH), PEG 4000 (20% w/v), isopropanol (10% v/v)] or 1 lL of the reservoir solution containing CAM (1 mM), respectively. Irregularly shaped crystals, 40-60 lm in each of the three dimensions were formed in 7-10 days when incubated at 22 C against the respective reservoir solutions. The crystals were gradually transferred into the reservoir solution containing glycerol (15% v/v) and flash frozen in liquid nitrogen.
Data collection and structure determination
X-ray diffraction data were collected at 100 K at the Â25 beamline of the National Synchrotron Light Source at the Brookhaven National Laboratory. The data were processed with HKL2000. 51 The crystals of apo-CAT I and CAT I -CAM complex were in the P2 1 and P1 space groups, respectively. The structures of both apo-CAT I and CAT I -CAM complex were determined by molecular replacement with MOLREP 52 as described in Results. The locations of the CAM molecules in the active sites of CAT I were clearly identified and positioned in the omit Fo-Fc density and then refined. The structures were iteratively manually built and refined using programs Coot 53 and REFMAC, 54 respectively. The data collection and refinement statistics are given in Table I . The structures of apo-CAT I and CAT I -CAM complex were deposited in the Protein Data Bank with accession codes 3U9B and 3U9F, respectively.
